Nanjing Legend Biotech Co.
Clinical trials sponsored by Nanjing Legend Biotech Co., explained in plain language.
A biopharmaceutical company developing cell therapies for cancer and other diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Experimental cell therapy takes on lupus and muscle disease
Disease control Recruiting nowThis early-stage trial is testing a new treatment called LUCAR-G79D for people with lupus or inflammatory myopathies that haven't responded to standard therapies. The treatment involves giving patients specially engineered immune cells to help control their disease. The study is …
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cell therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new cell therapy called LCAR-F33S in 35 people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to attack the cancer. The main goals are to check safet…
Phase: NA • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC